Dr. Barry R. Davis, Guy S. Parcel Chair in Public Health and professor of biostatistics at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, has been appointed to the Federal Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee.
The committee reviews and evaluates data concerning the safety and efficacy of drugs for use in the treatment of cardiovascular and renal disorders and makes recommendations to the Commissioner of Food and Drug Products. The committee is a division of the FDA’s Center for Drug Evaluation Research.
“My nomination and subsequent appointment to the FDA Cardiovascular and Renal Drugs Advisory Committee is a privilege and I will do my best to represent the interests of the public and the scientific community,” said Davis.
Dr. Davis will represent the field of biostatistics on the committee, which includes experts in cardiology, hypertension, arrhythmia, angina, congestive heart failure and diuresis. He was recommended and selected for the four-year appointment based on his work in the design and analysis of clinical trials and his frequent participation in major cardiovascular clinical trials.
At UTHealth School of Public Health, Davis directs the Coordinating Center for Clinical Trials (CCCT). The goal of the center is to identify important public health problems and design large clinical trials to study the efficacy of appropriate interventions, including the collection, management, reporting and interpretation of study findings. CCCT has designed studies on cardiovascular disease, diabetes, sickle cell anemia and the use of blood products in a trauma setting.
Davis earned his medical degree at the University of California San Diego School of Medicine and received his PhD and master’s degree in applied mathematics from Brown University. He has been a faculty member at UTHealth since 1983.
Read the story here.